Last reviewed · How we verify
Nivolumab Injectable Product
At a glance
| Generic name | Nivolumab Injectable Product |
|---|---|
| Also known as | immune checkpoint inhibitor, OPDIVO |
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (PHASE1)
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (PHASE1)
- Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors (PHASE1)
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) (PHASE1)
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (PHASE2)
- Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC (PHASE2)
- HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (PHASE1)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nivolumab Injectable Product CI brief — competitive landscape report
- Nivolumab Injectable Product updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI